馬用医薬品・サプリメント市場- 世界の産業規模、シェア、動向、機会、予測、製品別、流通チャネル別、地域別、競合別、2020～2030年

馬用医薬品・サプリメントの世界市場規模は2024年に9億7,289万米ドルとなり、2030年までの年間平均成長率（CAGR）は5.90％と予測され、予測期間中に大幅な成長が見込まれています。

この市場には、馬の健康と福祉を促進することを目的とした幅広い製品とサービスが含まれます。この市場には、馬の健康維持、パフォーマンスの向上、さまざまな病状への対処を目的として、馬のために特別に設計された医薬品、栄養補助食品、ヘルスケアサービスが含まれます。例えば、2024年3月、米国馬医学会（AAEP）は、米国で流行している5つの重要な馬の病気（西ナイルウイルス、破傷風、馬脳脊髄炎、狂犬病）に対する最新のワクチン接種プロトコルを発表しました。これらの病気には、予防活動を強化し、全国の馬の健康と安全を確保するためのプロトコルが整備されています。

主な市場促進要因

馬の個体数増加

主な市場課題

偽造品

主な市場動向：

天然およびハーブサプリメント

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の馬用医薬品・サプリメント市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（医薬品、サプリメント）
  • 流通チャネル別（ドラッグストア、動物病院、その他）
  • 地域別
  • 企業別（2024年）
• 製品市場マップ
  • 製品別
  • 流通チャネル別
  • 地域別

第6章 北米の馬用医薬品・サプリメント市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の馬用医薬品・サプリメント市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の馬用医薬品・サプリメント市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の馬用医薬品・サプリメント市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの馬用医薬品・サプリメント市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Zoetis Inc
• Boehringer Ingelheim GmbH
• Merck & Co Inc
• Elanco Animal Health Inc
• Bayer AG
• Ceva Sante Animale SA
• Virbac SA
• Vetoquinol SA
• Affymetrix Inc
• Celltrion Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

The global Equine Pharmaceuticals & Supplements market was valued at USD 972.89 million in 2024 and is expected to experience substantial growth during the forecast period, with a projected compound annual growth rate (CAGR) of 5.90% through 2030. This market includes a wide range of products and services aimed at promoting the health and well-being of horses. It encompasses pharmaceuticals, nutritional supplements, and healthcare services specifically designed for equines, with the goal of maintaining their health, improving performance, and addressing various medical conditions. For example, in March 2024, the American Association of Equine Practitioners (AAEP) released updated vaccination protocols for five critical equine diseases prevalent in the U.S. These diseases-West Nile virus, tetanus, equine encephalomyelitis, and rabies-have protocols designed to improve prevention efforts and ensure the health and safety of horses nationwide.

Key Market Drivers:

Increasing Equine Population

The global equine industry has seen a notable and steady rise in the equine population, which has significantly influenced the growth of the Equine Pharmaceuticals & Supplements market. There has been a marked increase in participation in equestrian activities such as horse riding, show jumping, and dressage, leading to a higher demand for horses for both sporting and recreational purposes. Beyond sports and leisure, horses are vital in industries such as agriculture, tourism, therapy, and law enforcement. As these sectors grow, the need for a larger equine workforce has also increased. Additionally, horses have become increasingly popular as companion animals, contributing to a surge in ownership.

Key Market Challenges:

Counterfeit Products

The presence of counterfeit equine pharmaceuticals and supplements remains a significant challenge. These products are often of subpar quality, containing incorrect ingredients or dosages, which could endanger the health of horses and undermine consumer confidence in the market.

Key Market Trends:

Natural and Herbal Supplements

A growing trend within the equine supplements market is the rising demand for natural and herbal alternatives. Horse owners are increasingly seeking holistic solutions to equine health, opting for supplements made from herbs, botanicals, and plant-based ingredients known for their therapeutic benefits. These products are perceived as gentler alternatives to conventional pharmaceuticals.

Key Market Players:

• Zoetis Inc
• Boehringer Ingelheim GmbH
• Merck & Co Inc
• Elanco Animal Health Inc
• Bayer AG
• Ceva Sante Animale SA
• Virbac SA
• Vetoquinol SA
• Affymetrix Inc
• Celltrion Inc

Report Scope:

This report segments the global Equine Pharmaceuticals & Supplements market into the following categories, and provides insights into the industry trends:

By Product:

• Pharmaceuticals
• Supplements

By Distribution Channel:

• Drug Stores
• Veterinary Hospitals
• Other Channels

By Region:

• North America: United States, Canada, Mexico
• Europe: Germany, United Kingdom, France, Italy, Spain
• Asia-Pacific: China, Japan, India, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Competitive Landscape and Company Profiles:

This section provides a detailed analysis of the key players in the global Equine Pharmaceuticals & Supplements market.

Available Customizations:

TechSci Research offers customized reports based on specific market data for the Global Equine Pharmaceuticals & Supplements market, catering to individual business needs. Customization options include the profiling and analysis of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Equine Pharmaceuticals & Supplements Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Pharmaceutical, Supplement)
  • 5.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Distribution Channel
  • 5.3.3. By Region

6. North America Equine Pharmaceuticals & Supplements Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Pharmaceutical, Supplement)
  • 6.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Equine Pharmaceuticals & Supplements Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Equine Pharmaceuticals & Supplements Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Equine Pharmaceuticals & Supplements Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel

7. Europe Equine Pharmaceuticals & Supplements Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Pharmaceutical, Supplement)
  • 7.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Equine Pharmaceuticals & Supplements Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. United Kingdom Equine Pharmaceuticals & Supplements Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. France Equine Pharmaceuticals & Supplements Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Equine Pharmaceuticals & Supplements Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Equine Pharmaceuticals & Supplements Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Equine Pharmaceuticals & Supplements Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Pharmaceutical, Supplement)
  • 8.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Equine Pharmaceuticals & Supplements Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Japan Equine Pharmaceuticals & Supplements Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. India Equine Pharmaceuticals & Supplements Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. Australia Equine Pharmaceuticals & Supplements Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. South Korea Equine Pharmaceuticals & Supplements Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Distribution Channel

9. South America Equine Pharmaceuticals & Supplements Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Pharmaceutical, Supplement)
  • 9.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Equine Pharmaceuticals & Supplements Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Equine Pharmaceuticals & Supplements Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Equine Pharmaceuticals & Supplements Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Equine Pharmaceuticals & Supplements Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Pharmaceutical, Supplement)
  • 10.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Equine Pharmaceuticals & Supplements Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Equine Pharmaceuticals & Supplements Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Equine Pharmaceuticals & Supplements Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel
  • 10.3.4. Kuwait Equine Pharmaceuticals & Supplements Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc
• 14.2. Boehringer Ingelheim GmbH
• 14.3. Merck & Co Inc
• 14.4. Elanco Animal Health Inc
• 14.5. Bayer AG
• 14.6. Ceva Sante Animale SA
• 14.7. Virbac SA
• 14.8. Vetoquinol SA
• 14.9. Affymetrix Inc
• 14.10. Celltrion Inc

15. Strategic Recommendations

16. About Us & Disclaimer